Response Pharmaceuticals

VA - Falls ChurchPharmaceutical3 H-1B visas (FY2023)

Focus: Response Pharmaceuticals is a public-stage pharmaceutical company headquartered in Falls Church, VA, specializing in treatments for weight management and metabolic disease with a diverse pipeline spanning metabolic diseases and neurology.

Metabolic Diseases Neurology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Response Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Response Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Non-invasive diagnostic testing

Influenza

N/A

Clinical Trials (1)

NCT00636662FLU A+B Nasal Swab Clinical Study

N/A

Help build intelligence for Response Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 32 programs across high-priority therapeutic areas (metabolic disease, neurology, infectious disease) with 3 Phase 3 programs providing near-term catalysts
Public company status with established infrastructure and credibility, offering career stability and growth potential in a focused specialty pharma environment
Strong H1B visa sponsorship record (3 approvals, 0 denials in 2023) indicates commitment to global talent acquisition

Watch Out For

Currently zero open job positions publicly listed, suggesting minimal active hiring or potential organizational constraints
Highly fragmented pipeline with limited commercial products and unclear revenue base creates uncertainty about company financial health and long-term runway
Weak publication output (0 publications) and missing critical financial data (revenue, R&D spend, cash position) raises transparency and research validation concerns

Generated by Claude from Response Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Beta-hCG Test Reference Range Determination

Healthy

N/A

Clinical Trials (1)

NCT03485313Beta-hCG Test Reference Range Determination

N/A

Option B+

HIV/AIDS

N/A

Clinical Trials (1)

NCT01891799Swaziland Safe Generations

N/A

Microclinic Water Program

Household Water Treatment

N/A

Clinical Trials (1)

NCT01907945Healthy Networks Water Treatment Study

N/A

RAMP 200

Acute Coronary Syndrome

N/A

Clinical Trials (1)

NCT02191735RAMP 200 / RAMP Cardiovascular Tests at the Point-of-Care

N/A

Artesunate

Malaria, Falciparum

N/A

Clinical Trials (1)

NCT00479206Artemisinin Resistance in Cambodia

N/A

New Viviscal Professional Supplement

Hair Thinning

N/A

Clinical Trials (1)

NCT02302053Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair

N/A

HIV-1 Immunogen

HIV Infections

N/A

Clinical Trials (1)

NCT00002172An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

N/A

Viviscal Extra-Strength Supplement

Hair Thinning

N/A

Clinical Trials (1)

NCT02297360Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair

N/A

Procalcitonin Test Reference Range Determination

Healthy

N/A

Clinical Trials (1)

NCT02591121Procalcitonin Test Reference Range Determination

N/A

Microclinic

HIV

N/A

Clinical Trials (1)

NCT02474992The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care

N/A

Differentiated service delivery approach

Focus of the Study is to Evaluate DSD Models for Both TB Treatment and TPT Usiing Key Performance Indicators

N/A

Clinical Trials (1)

NCT06883643Adoption of Innovative Approaches to Ensure Continuity of Quality TB Services During COVID-19 Pandemic in Lusaka and Livingstone, Zambia. (Telemedicine in TB)

N/A

Mfangano Health Net Microclinic Program

HIV

N/A

Clinical Trials (1)

NCT01912521Mfangano Island Healthy Networks Impact Study

N/A

Viviscal Oral Supplement Tablets

Hair Thinning

N/A

Clinical Trials (1)

NCT02288858To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

N/A

HIV-1 Immunogen

HIV Infections

N/A

Clinical Trials (1)

NCT00002173An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

N/A

Fluxmed GrH portable pneumotachograph

Out-of-Hospital Cardiac Arrest

N/A

Clinical Trials (1)

NCT04237727CAvent-Ventilation During Advanced Cardiopulmonary Resuscitation in Out-of-hospital Cardiac Arrest- an Observational Study

N/A

RDX-002

Drug-induced Weight Gain

Phase 1

Clinical Trials (1)

NCT05857566Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Phase 1

NeuroVax

Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT02200718A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Phase 1

HIV-1 Immunogen

HIV Infections

Phase 1

KD026

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT02434744Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Phase 2

SLx-4090

Hyperlipidemia

Phase 2

Clinical Trials (1)

NCT00810979Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Phase 2

SLx-2101

Hypertension

Phase 2

SLx-4090

Hypertriglyceridemia

Phase 2

Clinical Trials (1)

NCT00562575Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

Phase 2

SLx-2101

Hypertension

Phase 2

RDX-002

Triglycerides

Phase 2

Clinical Trials (1)

NCT06640972Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

Phase 2

NeuroVax

Multiple Sclerosis

Phase 2

Clinical Trials (1)

NCT02149706A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Phase 2

SLx-4090

Type 2 Diabetes

Phase 2

Clinical Trials (1)

NCT00871936A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

Phase 2

REMUNE

HIV/AIDS

Phase 2

Clinical Trials (1)

NCT02291809REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

Phase 2

SLx-2101

Raynaud's Disease

Phase 2

Clinical Trials (1)

NCT00528242Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Phase 2

NeuroVax

Secondary Progress Multiple Sclerosis

Phase 2/3

Clinical Trials (1)

NCT02057159A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Phase 2/3

IR103

HIV

Phase 3

Clinical Trials (1)

NCT02366026REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

Phase 3

Ervebo

Ebola Virus Disease

Phase 3

Clinical Trials (1)

NCT06841614EBOla Post-Exposure Prophylaxis

Phase 3

HIV-1 Immunogen

HIV Infections

Phase 3

Clinical Trials (1)

NCT00002359A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

Phase 3

Artesunate

Malaria

Phase 4

Clinical Trials (1)

NCT01976780In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

Phase 4

Artesunate/mefloquine

Malaria

Phase 4

Clinical Trials (1)

NCT02052323Harmonized AS/MQ Efficacy Study - Thailand